组蛋白去乙酰化酶2在人舌鳞状细胞癌中的表达
A Study on Expression of Histone Deacetylase-2 in Humantongue Squamous Cell Carcinomas
-
摘要: 目的 采用免疫组织化学染色的方法, 研究组蛋白去乙酰化酶2 (HDAC2) 蛋白在人舌正常粘膜, 不典型增生及鳞状细胞癌中的表达, 并分析其与患者的临床指标及生存状况的相关性.方法 标本分为:舌鳞状细胞癌组 (n=96) 、舌粘膜不典型增生组 (n=24) 、正常舌粘膜组 (n=13) 行免疫组织化学染色, 阳性细胞占比≥5%为阳性.Kaplan-Merier生存分析法分析患者生存状况.结果 96例舌鳞状细胞癌样本中有86例为阳性表达 (89.6%) , HDAC2的过表达与患者年龄、性别、烟酒嗜好、病理分级、淋巴结转移等因素之间的差异无统计学意义 (P>0.05) , 但与癌症的TNM分期之间差异有统计学意义 (P<0.001) .24例不典型增生组织中有14例 (58.3%) 呈阳性表达, 正常舌粘膜组织中有7例 (53.8%) 阳性表达样本.HDAC2蛋白在舌鳞状细胞癌患者中的阳性表达率显著高于不典型增生组和正常舌粘膜组 (P<0.00) .HDAC2的表达与患者术后生存情况之间无相关性 (P=0.184) , 有淋巴结转移的患者术后生存时间明显短于无淋巴结转移的患者 (P<0.000) .结论 HDAC2在人舌鳞状细胞癌中的阳性表达率明显高于不典型增生组和正常舌粘膜组.HDAC2阳性表达的患者肿瘤分期级别较高, 并且有淋巴结转移者的术后生存时间明显低于无淋巴结转移者.提示HDAC2可作为舌鳞癌预后的一个可靠的分子参考指标.Abstract: Objective To study the expression of HDAC2 and the correlations with pathological parameters in human tongue squamous cell carcinoma, and to analyze the correlation between them and patients' clinical indicators and survival status.Methods A total of 96 cases of humantongue squamous cell carcinoma (SCC) , 24 dysplasia (ED) , 13 normal mucosa (NOM) were involved in this study. The expression of HDAC2 was evaluated by ICH. Kaplan-Meier was used to research cumulative surviving of SCC patients.Result Among 96 cases of SCC samples, 86 cases showed positive expression (89.6%) , The differences between the overexpression of HDAC2 and the pathological grading, lymph node metastasis, the patient's age and gender were insignificant (all P>0.05) . However, the differences of TNM presented statistically significant (χ2 = 18.600, P<0.001) . 14 out of 24 ED (58.3%) were positive expression of HDAC2, there were 7 cases (53.8%) of positive expression samples in NOM. The expression of HDAC2 in SCCs was significantly higher than that in ED and NOM (χ2= 118.407, P<0.00) . There was no significant difference of cumulative surviving between the positive and negative SCC patients (P = 0.184) . However cumulative surviving of patients with lymph node metastasis was significantly shorter than those with no metastasis (P<0.000) .Conclusions The expression of HDAC2 in SCC was significantly higher than that in ED and NOM, the TNM stage of patients presented the significant difference of expression of HDAC2, patients with lymph node metastasis were significantly shorter than those with no metastasis, and demonstration can be used as a reliable reference molecule for the evaluating prognosis of SCC.
-
[1]温玉明.口腔颌面部肿瘤学, 现代理论与临床实践[M].北京:人民卫生出版社, 2004:19-33. [2] [2]RAPIDIS A D, VERMORKEN J B, BOURHIS J, et al.Novel Targeted therapies in head and neck cancer:past, present and future[J].Reviews on Recent Clinical Trials, 2008, 3 (3) :156-166. [3] [3]SCULLY C, FELIX D H.Oral medicine-up date for thedental practitioner oral cancer[J].British Dental Journal, 2006, 200 (1) :13-17. [4]钟理, 杨春燕, 组蛋白去乙酰化酶 (HDACs) 及其调控的研究进展[J], 中国农学通报, 2014, 30 (21) :1-8. [5]周昊, 陈坤, 张铁柱, 舌鳞癌侵袭及转移的相关肿瘤标志物研究进展[J].医学综述, 2014, 20 (11) :1982-1983. [6]姜力豪, 欧阳举.舌鳞状细胞癌研究进展[J].现代医药卫生, 2014, 30 (23) :3566-3568. [7] [7]GLOZAK M A, SETO E.Histonedeacetylases and cancer[J].Oncogene, 2007, 26 (37) :5420-5432. [8] [8]LANE A A, CHABNER B A.Histonedeacetylase inhibitors in cancer therapy[J].Journal of Clinical Oncology, 2009, 27 (32) :5459-5468. [9] [9]KOURAKLIS G, THEOCHARIS S, PATSOURIS E, et al.Histonedeacetylase inhibitors:anovel target of anticancer therapy (review) [J].Oncology Reports, 2006, 15 (2) :489-494. [10] [10]JAHAN S, SUN J M, HE S, et al.Transcription-dependent association of HDAC2 with active chromatin[J].Cellular Physiology, 2018, 233 (2) :1650-1657. [11] [11]ROPERO S, BALLESTAR E, ALAMINOS M, et al.Transforming pathways unleashed by a HDAC2 mutationin human cancer[J].Oncogene, 2008, 27 (28) :4008-4012. [12] [12]MULLER B M, JANA L, KASAJIMA A, et al.Differential expression of histonedeacetylases HDAC1, 2and 3 in humancancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of diseaseprogression[J].BMCC Ancer, 2013, 13 (215) :2-8. [13] [13]STOJANOVIC N, HASSAN Z, WIRTH M, et al.HDAC1and HDAC2 integrate the expression of P53 mutants in pancreatic cancer[J].Oncogene, 2017, 36 (13) :1804-1815. [14] [14]WENG W Q, JIANG Y Y, YU H M, et al.HDAC2overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer[J].American Journal of Cancer Research, 2017, 7 (5) :1213-1226. [15] [15]Stamatios Theocharis.Histonedeacetylase-1 and-2 expression in mobile tongue squamous cell carcinoma:associations with clinicopathological parameters and patients survival[J].Oral Pathology Medicine, 2011, 40 (9) :706-714. [16] [16]HAO-HUENG CHANG, CHUN-PIN CHIANG, KUO YP, etal.Histonedeacetylase 2 expression predicts poorer prognosis in oral cancer patients[J].Oral Oncology, 2009, 45 (7) :610-614. -
点击查看大图
计量
- 文章访问数: 2487
- HTML全文浏览量: 907
- PDF下载量: 83
- 被引次数: 0
下载:
